Effects of repetitive superficial chemical peels on facial sebum secretion in acne patients

BACKGROUND: Glycolic acid and Jessner's solution are popular superficial chemical peel agents for the treatment of facial acne, and increased sebum secretion is one of the major aetiological factors of acne. OBJECTIVE: To compare the effects of 30% glycolic acid peels and Jessner's solution peels on sebum secretion in facial acne patients. METHODS: Thirty-eight patients with mild to moderate facial acne were included. Twenty-seven patients were treated with 30% glycolic acid peels and 11 patients with Jessner's solution peels. Each peel was performed twice with an interval of 2 weeks. Before and 2 weeks after each peel, sebum levels of forehead, nose, chin and cheeks were measured by using a Sebumeter (SM810 Courage & Khazaka, Cologne, Germany). RESULTS: The sebum levels were not significantly changed by two peels treatments of 30% glycolic acid peels or Jessner's solution peels on the facial skins of patients with facial acne. CONCLUSIONS: The two types of peels, 30% glycolic acid peels and Jessner's solution peels, did not affect sebum secretion of the facial skins of patients with facial acne after the two peels treatments. The accumulative effects of more than two peels treatments using these modalities need further evaluation.     

从肝论治头痛

头痛为中医脑病科的常见病、多发病。中医学认为,内伤头痛在生理病理上与肝关系密切。笔者试从肝论治内伤头痛,若肝气郁滞者,治以疏肝理气之法;肝血瘀阻者,治以活血通络之法;肝阳上亢者,治以平肝潜阳之法;肝血亏虚者,治以养肝补血之法;肝肾亏虚者,治以培补肝肾之法。并举临床验案1例,以资佐证疏肝活血的具体运用。     

Safety of alectinib for the treatment of metastatic ALK-rearranged non-small cell lung cancer

Introduction: Patients with anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer (NSCLC) may derive significant clinical benefit from targeted therapies against this driver mutation, but progression is virtually inevitable. Alectinib is a next-generation ALK inhibitor that provides a novel treatment option for this group of patients.

Areas covered: In this review, we summarize the overall safety and tolerability of alectinib. Specifically, we cover cardiovascular, gastrointestinal, hepatic, musculoskeletal, and respiratory adverse events. The safety profile of alectinib is also described in special populations and in comparison with other ALK inhibitors.

Expert opinion: Alectinib is a well-tolerated tyrosine kinase inhibitor and should be considered for patients with ALK-rearranged NSCLC. The question then arises as to how to choose a next-generation ALK inhibitor in the second-line setting. Understanding acquired resistant mechanisms has become essential. Whether or not to use alectinib in the first-line setting is extremely controversial, but we anticipate its approval for this indication and availability in more countries in the near future.     

温州市鹿城区预防接种室消毒与污染状况调查

为了解我区预防接种室局部消毒的质量和微环境污染状况,对我区街道和村的预防注射室消毒及污染情况进行了调查。其中酒精消毒液浓度、染菌量和空气、操作台面、手染菌量合格率分别为37．5％、36．6％、38．1％、68．3％、43．2％．街道卫生院的酒精消毒液浓度、台面和手染菌量合格率高于村卫生室;酒精和空气染菌量街道卫生院和村卫生室两级单位无明显差别。一次性注射器无菌试验合格率为100％．调查结果表明,我区预防注射室的消毒质量不高,环境污染比较严重。本文分析了原因,提出了改进建议。